Please find attached outcome of Board Meeting held on July 31, 2025 for approval of unaudited financial results for the Q1FY26, approval of dividend and other items
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 2.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mankind Pharma's board approved Q1FY26 (quarter ended June 30, 2025) unaudited results and declared an interim dividend of ₹1 per share (100% on face value), with record date set as August 8, 2025. Standalone revenue from operations rose modestly to ₹2,541.36 crores from ₹2,412.62 crores YoY (~5.3% growth), while standalone profit after tax declined to ₹412.76 crores from ₹476.42 crores YoY (~13% drop), with basic EPS at ₹10.00 vs ₹12.62. Consolidated revenue jumped to ₹3,570.35 crores from ₹2,867.85 crores YoY (~24.5% growth), boosted by the October 2024 acquisition of Bharat Serums and Vaccines (BSV). The board approved acquiring BSV's Women Health Rx branded generic business through a slump sale, and cleared raising up to ₹1,000 crores via commercial papers. Auditors flagged an emphasis of matter on ongoing income tax proceedings involving disallowances of over ₹1,500 crores, which the company is contesting.
The interim dividend and BSV Women Health acquisition signal continued capital deployment for growth, but standalone PAT decline and higher finance costs (₹146.70 cr vs ₹10.84 cr YoY) due to acquisition debt may pressure near-term margins. The unresolved tax demand of ~₹1,534 crores remains a key overhang to monitor despite management's confidence in appeals.